Calcium channel blocker in patients with chronic kidney disease
Authors:
Open Access
- 8 November 2021
- journal article
- review article
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 26 (3) , 207-215
Abstract
Background: Chronic kidney disease (CKD) is involved in a progressive deterioration in renal function over the years and is now a global public health problem. Currently, reducing the number of patients progressing to end-stage renal failure is urgently necessary. Hypertension and CKD interact with each other, and good control of blood pressure (BP) can improve CKD patients’ prognosis. With the current global trend for more strict BP control, the importance of BP management and the need for medication to achieve this strict goal are increasing. Calcium channel blockers (CCBs), which target voltage-dependent calcium channels, are frequently used in combination with renin–angiotensin–aldosterone system inhibitors for CKD patients because of their strong BP-lowering properties and relatively few adverse side effects. Calcium channels have several subtypes, including L, N, T, P/Q, and R, and three types of CCBs, L-type CCBs, L-/T-type CCBs, and L-/N-type CCBs, that are available. Nowadays, the new functions and effects of the CCBs are being elucidated. Conclusion: We should use different types of CCBs properly depending on their pharmacological effects, such as the strength of antihypertensive effects and the organ protection effects, taking into account the pathophysiology of the patients. In this article, the role and the use of CCBs in CKD patients are reviewed.Keywords
Funding Information
- Japan Society for the Promotion of Science (20K08633, 21K16189, 21K17278)
This publication has 67 references indexed in Scilit:
- Efficacy and Safety of Combined vs. Single Renin-Angiotensin-Aldosterone System Blockade in Chronic Kidney Disease: A Meta-AnalysisAmerican Journal of Hypertension, 2013
- Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysisDiabetologia, 2011
- Functional Importance of L- and P/Q-Type Voltage-Gated Calcium Channels in Human Renal VasculatureHypertension, 2011
- Benidipine, a dihydropyridine L-type/T-type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive ratsJournal Of Hypertension, 2010
- Different Effects of L/N-Type and L-Type Calcium Channel Blockers on the Renin-Angiotensin-Aldosterone System in SHR/IzmAmerican Journal of Nephrology, 2009
- CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004American Journal of Kidney Diseases, 2008
- Effects of Vasopeptidase Inhibition on Renal Function and Tubuloglomerular Feedback in Spontaneously Hypertensive RatsHypertension Research, 2005
- Characterization of three types of calcium channel in the luminal membrane of the distal nephronCanadian Journal of Physiology and Pharmacology, 2004
- Tubular and cellular localization of the cardiac L-type calcium channel in rat kidneyKidney International, 2002
- Disparate Effects of Calcium Antagonists on Renal Microcirculation.Hypertension Research, 1996